Urinary Cotinine and Cotinine + Trans-3'-Hydroxycotinine (TNE-2) Cut-points for Distinguishing Tobacco Use from Nonuse in the United States: PATH Study (2013-2014).
Journal
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
ISSN: 1538-7755
Titre abrégé: Cancer Epidemiol Biomarkers Prev
Pays: United States
ID NLM: 9200608
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
received:
30
06
2020
revised:
11
12
2020
accepted:
23
03
2021
pubmed:
9
4
2021
medline:
27
1
2022
entrez:
8
4
2021
Statut:
ppublish
Résumé
Determine the overall, sex-, and racially/ethnically-appropriate population-level cotinine and total nicotine equivalents (TNE-2, the molar sum of the two major nicotine metabolites) cut-points to distinguish tobacco users from nonusers across multiple definitions of use (e.g., exclusive vs. polytobacco, and daily vs. non-daily). Using Wave 1 (2013-2014) of the U.S. Population Assessment of Tobacco and Health (PATH) Study, we conducted weighted Receiver Operating Characteristic (ROC) analysis to determine the optimal urinary cotinine and TNE-2 cut-points, stratified by sex and race/ethnicity. For past 30-day exclusive cigarette users, the cotinine cut-point that distinguished them from nonusers was 40.5 ng/mL, with considerable variation by sex (male: 22.2 ng/mL; female: 43.1 ng/mL) and between racial/ethnic groups (non-Hispanic other: 5.2 ng/mL; non-Hispanic black: 297.0 ng/mL). A similar, but attenuated, pattern emerged when assessing polytobacco cigarette users (overall cut-point = 39.1 ng/mL, range = 5.5 ng/mL-80.4 ng/mL) and any tobacco users (overall cut-point = 39.1 ng/mL, range = 4.8 ng/mL-40.0 ng/mL). Using TNE-2, which is less impacted by racial differences in nicotine metabolism, produced a comparable pattern of results although reduced the range magnitude. Because of similar frequency of cigarette use among polytobacco users, overall cut-points for exclusive cigarette use were not substantially different from cut-points that included polytobacco cigarette use or any tobacco use. Results revealed important differences in sex and race/ethnicity appropriate cut-points when evaluating tobacco use status and established novel urinary TNE-2 cut-points. These cut-points may be used for biochemical verification of self-reported tobacco use in epidemiologic studies and clinical trials.
Sections du résumé
BACKGROUND
Determine the overall, sex-, and racially/ethnically-appropriate population-level cotinine and total nicotine equivalents (TNE-2, the molar sum of the two major nicotine metabolites) cut-points to distinguish tobacco users from nonusers across multiple definitions of use (e.g., exclusive vs. polytobacco, and daily vs. non-daily).
METHODS
Using Wave 1 (2013-2014) of the U.S. Population Assessment of Tobacco and Health (PATH) Study, we conducted weighted Receiver Operating Characteristic (ROC) analysis to determine the optimal urinary cotinine and TNE-2 cut-points, stratified by sex and race/ethnicity.
RESULTS
For past 30-day exclusive cigarette users, the cotinine cut-point that distinguished them from nonusers was 40.5 ng/mL, with considerable variation by sex (male: 22.2 ng/mL; female: 43.1 ng/mL) and between racial/ethnic groups (non-Hispanic other: 5.2 ng/mL; non-Hispanic black: 297.0 ng/mL). A similar, but attenuated, pattern emerged when assessing polytobacco cigarette users (overall cut-point = 39.1 ng/mL, range = 5.5 ng/mL-80.4 ng/mL) and any tobacco users (overall cut-point = 39.1 ng/mL, range = 4.8 ng/mL-40.0 ng/mL). Using TNE-2, which is less impacted by racial differences in nicotine metabolism, produced a comparable pattern of results although reduced the range magnitude.
CONCLUSIONS
Because of similar frequency of cigarette use among polytobacco users, overall cut-points for exclusive cigarette use were not substantially different from cut-points that included polytobacco cigarette use or any tobacco use. Results revealed important differences in sex and race/ethnicity appropriate cut-points when evaluating tobacco use status and established novel urinary TNE-2 cut-points.
IMPACT
These cut-points may be used for biochemical verification of self-reported tobacco use in epidemiologic studies and clinical trials.
Identifiants
pubmed: 33827982
pii: 1055-9965.EPI-20-0997
doi: 10.1158/1055-9965.EPI-20-0997
pmc: PMC10337127
mid: NIHMS1912114
doi:
Substances chimiques
Biomarkers
0
hydroxycotinine
27323-64-4
Cotinine
K5161X06LL
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
1175-1184Subventions
Organisme : NIDA NIH HHS
ID : HHSN271201100027C
Pays : United States
Organisme : NIDA NIH HHS
ID : HHSN271201600001C
Pays : United States
Informations de copyright
©2021 American Association for Cancer Research.
Références
JAMA Netw Open. 2018 Dec 7;1(8):e185937
pubmed: 30646298
Vital Health Stat 2. 1969 Jan;(31):1-24
pubmed: 5306564
N Engl J Med. 2017 Sep 21;377(12):1111-1114
pubmed: 28813211
J Pharmacol Exp Ther. 2002 May;301(2):594-8
pubmed: 11961061
MMWR Morb Mortal Wkly Rep. 2015 Feb 6;64(4):103-8
pubmed: 25654612
Sci Total Environ. 2016 Jul 1;557-558:676-80
pubmed: 27037889
Am J Public Health. 2015 Jun;105(6):1098-100
pubmed: 25521901
BMC Public Health. 2011 Jun 29;11:512
pubmed: 21714876
Nicotine Tob Res. 2016 Nov;18(11):2065-2074
pubmed: 27190401
JAMA. 1998 Jul 8;280(2):152-6
pubmed: 9669788
J Pharmacol Exp Ther. 2004 Sep;310(3):1208-15
pubmed: 15084646
Pharmacol Rev. 2005 Mar;57(1):79-115
pubmed: 15734728
Nicotine Tob Res. 2020 Jun 12;22(7):1086-1097
pubmed: 31570931
Tob Control. 2016 Nov;25(Suppl 2):ii14-ii20
pubmed: 27729565
Cancer Epidemiol Biomarkers Prev. 2010 Nov;19(11):2795-800
pubmed: 20805316
Cancer Epidemiol Biomarkers Prev. 2007 Apr;16(4):820-2
pubmed: 17416777
MMWR Morb Mortal Wkly Rep. 2019 Nov 15;68(45):1013-1019
pubmed: 31725711
Chem Res Toxicol. 2003 Aug;16(8):988-93
pubmed: 12924926
J Anal Toxicol. 2005 Nov-Dec;29(8):814-8
pubmed: 16374940
Am J Prev Med. 2016 Nov;51(5):682-692
pubmed: 27423656
Carcinogenesis. 2014 Nov;35(11):2526-33
pubmed: 25233931
Tob Control. 2019 Nov;28(6):663-668
pubmed: 30297373
Tob Control. 2017 Jul;26(4):371-378
pubmed: 27507901
Am J Public Health. 1987 Nov;77(11):1435-8
pubmed: 3661797
Am J Epidemiol. 2001 Apr 15;153(8):807-14
pubmed: 11296155
Cochrane Database Syst Rev. 2016 May 27;(5):CD011856
pubmed: 27230795
Biomarkers. 2007 Sep-Oct;12(5):484-96
pubmed: 17701747
Nicotine Tob Res. 2003 Feb;5(1):111-6
pubmed: 12745512
Clin Chim Acta. 2014 Sep 25;436:290-7
pubmed: 24968308
Environ Health Perspect. 2016 Oct;124(10):1568-1574
pubmed: 27164619
Nicotine Tob Res. 2002 May;4(2):149-59
pubmed: 12028847
Nicotine Tob Res. 2011 Mar;13(3):202-8
pubmed: 21330276
Cochrane Database Syst Rev. 2016 Feb 04;2:CD005992
pubmed: 26842828
Cancer Epidemiol Biomarkers Prev. 2019 May;28(5):943-953
pubmed: 30733305
Am J Epidemiol. 2009 Jan 15;169(2):236-48
pubmed: 19019851
MMWR Morb Mortal Wkly Rep. 2018 Nov 09;67(44):1225-1232
pubmed: 30408019
N Engl J Med. 2017 Jan 26;376(4):342-353
pubmed: 28121512
Handb Exp Pharmacol. 2009;(192):29-60
pubmed: 19184645